Centinel Spine® Announces First International Use of 3D-Printed Porous Titanium FLX™ Platform

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the first international implantation of the 3D-Printed Porous Titanium FLX™ platform. Dr. Alfredo Guiroy and Dr. Jose Ricardo Prina in Argentina were the first surgeons outside the United States to implant the STALIF C FLX™ and STALIF M FLX™ devices.

The FLX platform represents the latest material evolution offered by Centinel Spine. The STALIF C FLX and STALIF M FLX devices are 3D-printed porous titanium Integrated Interbody™ implants that have been engineered to mimic bone. These implants provide equivalent subsidence performance to PEEK; contain a proprietary, interconnected FUSE-THRU™ lattice with a structure and modulus of elasticity similar to bone; and have optimized mechanical, visual, and osteophilic environments that reduce stress shielding, enable fusion assessment, and support bony in-growth, on-growth, and thru-growth.

“The STALIF M FLX cage has a bone contact surface much better and larger than any other PEEK cage of the same size and has a maximum capability of osteointegration with the bone,” said Dr. Prina. “We consider that this works much better for a stand-alone procedure.”

“It is my pleasure to use STALIF®. It’s a very good implant, with a lot of versatility due to different sizes and lordotic options, and titanium has shown to be more friendly for fusion than other PEEK/hybrid combinations,” commented Dr. Guiroy.

Centinel Spine’s CEO, Steve Murray, stated, “We are excited to be able to offer our state-of-the-art FLX technology to our international partners. As a company, we remain dedicated to continued innovation and furthering scientific evidence in advancing spine care. We are proud to be able to make our technology available to even more patients on a global scale.”

STALIF M FLX and STALIF C FLX implants are built upon the proven STALIF design, which has over 30 years of clinical history and has helped many patients regain their lives. STALIF implants provide compressive fixation at the fusion site, pulling the vertebral bodies onto the implant and graft material to enhance opportunities for fusion in line with Wolff’s Law of Bone Healing.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”